Impella 5.5: A Systematic Review of the Current Literature.

IF 1.6 Q2 SURGERY
Carlos Alberto Valdes, Ahmet Bilgili, Akshay Reddy, Omar Sharaf, Fabian Jimenez-Contreras, Griffin Stinson, Mustafa Ahmed, Juan Vilaro, Alex M Parker, Mohammad Az Al-Ani, Daniel Demos, Juan Aranda, Mark Bleiweis, Thomas M Beaver, Eric I Jeng
{"title":"Impella 5.5: A Systematic Review of the Current Literature.","authors":"Carlos Alberto Valdes, Ahmet Bilgili, Akshay Reddy, Omar Sharaf, Fabian Jimenez-Contreras, Griffin Stinson, Mustafa Ahmed, Juan Vilaro, Alex M Parker, Mohammad Az Al-Ani, Daniel Demos, Juan Aranda, Mark Bleiweis, Thomas M Beaver, Eric I Jeng","doi":"10.1177/15569845241266527","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device's clinical effectiveness, safety profile, patient outcomes, and relevant procedural considerations.</p><p><strong>Methods: </strong>We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/MEDLINE database. The search query included articles available from October 6, 2022, through January 13, 2023. Our initial search identified 75 studies. All records were screened by 2 independent reviewers using the Covidence software for adherence to our inclusion criteria, and 8 retrospective cohort studies were identified as appropriate for inclusion.</p><p><strong>Results: </strong>Across the included studies, the sample size ranged from 4 to 275, with predominantly male cohorts. Indications for Impella support varied, and the duration of support ranged from 9.8 to 70 days. Overall, Impella support appeared to be associated with favorable survival rates and manageable complications in various patient populations. Complications associated with Impella use included bleeding, stroke, and device malfunctions. Two studies compared prolonged and Food and Drug Administration-approved Impella support, showing similar outcomes and adverse events.</p><p><strong>Conclusions: </strong>Impella 5.5 continues to be an attractive option for bridging patients to definitive therapy. Survival during and after Impella 5.5 was favorable for patients regardless of initial indication. However, device use was associated with several important complications, which calls for judicious use and a precontemplated exit strategy. Limitations of this literature review include biases inherent to the retrospective studies included, such as selection and publication bias.</p>","PeriodicalId":13574,"journal":{"name":"Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/15569845241266527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device's clinical effectiveness, safety profile, patient outcomes, and relevant procedural considerations.

Methods: We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/MEDLINE database. The search query included articles available from October 6, 2022, through January 13, 2023. Our initial search identified 75 studies. All records were screened by 2 independent reviewers using the Covidence software for adherence to our inclusion criteria, and 8 retrospective cohort studies were identified as appropriate for inclusion.

Results: Across the included studies, the sample size ranged from 4 to 275, with predominantly male cohorts. Indications for Impella support varied, and the duration of support ranged from 9.8 to 70 days. Overall, Impella support appeared to be associated with favorable survival rates and manageable complications in various patient populations. Complications associated with Impella use included bleeding, stroke, and device malfunctions. Two studies compared prolonged and Food and Drug Administration-approved Impella support, showing similar outcomes and adverse events.

Conclusions: Impella 5.5 continues to be an attractive option for bridging patients to definitive therapy. Survival during and after Impella 5.5 was favorable for patients regardless of initial indication. However, device use was associated with several important complications, which calls for judicious use and a precontemplated exit strategy. Limitations of this literature review include biases inherent to the retrospective studies included, such as selection and publication bias.

Impella 5.5:当前文献的系统性回顾。
目的:Impella 5.5(Abiomed,美国马萨诸塞州丹佛斯)是一种用于心源性休克患者的临时机械循环支持装置。本综述全面概述了该装置的临床有效性、安全性、患者预后以及相关程序注意事项:我们根据《系统综述和元分析首选报告项目》指南,使用 PubMed/MEDLINE 数据库进行了系统综述。搜索查询包括 2022 年 10 月 6 日至 2023 年 1 月 13 日期间的文章。我们的初步搜索确定了 75 项研究。所有记录均由两名独立审稿人使用 Covidence 软件进行筛选,以确定是否符合我们的纳入标准,最终确定 8 项回顾性队列研究适合纳入:在所有纳入的研究中,样本量从 4 个到 275 个不等,主要是男性队列。Impella支持的适应症各不相同,支持时间从9.8天到70天不等。总体而言,Impella 支持似乎与不同患者群体的良好存活率和可控并发症有关。与使用 Impella 相关的并发症包括出血、中风和设备故障。两项研究比较了延长的Impella支持和食品药品管理局批准的Impella支持,结果和不良事件相似:Impella5.5仍然是将患者过渡到最终治疗的一个有吸引力的选择。无论初始适应症如何,患者在Impella 5.5期间和之后的存活率都很高。然而,设备的使用与几种重要的并发症有关,因此需要谨慎使用并预先考虑退出策略。本文献综述的局限性包括所纳入的回顾性研究固有的偏倚,如选择偏倚和发表偏倚。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
6.70%
发文量
80
期刊介绍: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery is the first journal whose main mission is to disseminate information specifically about advances in technology and techniques that lead to less invasive treatment of cardiothoracic and vascular disease. It delivers cutting edge original research, reviews, essays, case reports, and editorials from the pioneers and experts in the field of minimally invasive cardiothoracic and vascular disease, including biomedical engineers. Also included are papers presented at the annual ISMICS meeting. Official Journal of the International Society for Minimally Invasive Cardiothoracic Surgery
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信